The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
110 jobs Number of planned job losses
Announcement Date
25 September 2009
Employment effect (start)
1 October 2009
Foreseen end date
31 December 2009
Description
US pharmaceutical group Bristol-Myers Squibb has announced that the group will make 110 workers redundant with the closure of its plant in Epernon on 31 December 2009. Some other 30 workers will be transferred to the production plant in Agen (Lot-et-Garonne) and the remainder will be offered jobs at the company's headquarters in Rueil-Malmaison (Hauts-de-Seine).
The US group, which faces overcapacity in the production of ordinary drugs, has been trying to sell the plant for one year but did not manage to find a buyer. Bristol-Myers Squibb is also trying to sell the site of Meymac in central France.
Eurofound (2009), Bristol-Myers Squibb, Closure in France, factsheet number 69577, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/69577.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
